Loading...
Patients with symptomatic claudication due to peripheral artery disease commonly undergo endovascular revascularization, but long-term outcomes can be suboptimal due to restenosis and disease progression. Several novel approaches to incorporating local drug delivery (including drug-coated balloons and stents) still have relatively high rates of failure, particularly with very long lesions, heavily calcified lesions, and total occlusions. In a manufacturer-funded study (NCT02574481), 465 patients undergoing percutaneous revascularization of the superficial femoral or proximal popliteal artery were randomized in a 2:1 fashion to a recently FDA-approved paclitaxel-eluting stent (Eluvia) or an FDA-approved paclitaxel-coated stent (Zilver PTX). …